1,722,277 research outputs found
Remote monitoring of cardiac implantable electrical devices in Europe: Quo vadis?
No full textThis editorial refers to 'Implementation and reimbursement of remote monitoring for cardiac implantable electronic devices in Europe: a survey from the Health Economics Committee of the European Heart Rhythm Association' by G.H. Mairesse et al., on page 814-818
The Impact of Diabetes and Comorbidities on the Outcome of Heart Failure Patients Treated with Cardiac Resynchronization Therapy: Implications for Patient Management
No full textN/
The epidemiologic threat of atrial fibrillation: Need for secondary, primary, and primordial prevention
No full textN/
How to RESPOND to the quest to increase the effectiveness of cardiac resynchronization therapy?
Full text linkThis editorial refers to 'Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial', by J. Brugada et al., on page 730
A closer look into the complexity of our practice: Outcome research for transvenous temporary cardiac pacing
No full textN
How do cardiologists face health economics and health technology assessments?
No full textHow do cardiologists face health economics and health technology assessment
Spotlight Issue "Electrophysiology and cardiac device therapy: why and how to approach health economics?" Volume 13 Supplement 2 May 2011 of EP Europace
No full textThis is a special issue of EP-Europace, with G Boriani as Guest Editor. It is the result of an initiative of the Committee on Health Economics and Outcome Research of EHRA, chaired by G Boriani. EHRA is the acronym of European Heart Rhythm Association, a branch of the European Society of Cardiology and it is the leader association on Electrophysiology and Arrhthmia science in Europe. This issue covers a wide spectrum of topics, starting from an overview of economic evaluations, and then focusing on the disease burden and emerging costs of atrial fibrillation and heart failure, two growing epidemics in western countries. The emerging role of European registries, a cornerstone of outcome research and policy making is also highlighted, as well as the important contribution of patient associations in promoting and supporting the access to evidence-based therapies. The applications of economic evaluations to a series of treatments that carry a high up-front cost, such as cardioverter defibrillators, devices for CRT, and atrial fibrillation ablation procedures are discussed in articles co-authored by both electrophysiologists and health economists. Remote monitoring, a new option for improving both patient care and the organization of device clinics, is also discussed. Finally, the application of health economics in policy making, the need for an appropriate approach to treatment with medical devices, taking into consideration the differences with pharmacological treatments, and the possibility to base decision making on a multidisciplinary approach, such as health technology assessment, are debated. In this complex scenario, the heterogeneity of reimbursement practices and the need for a refinement of DRG (diagnosis-related groups) systems and for new strategies to sustain and enhance those effective technological innovations that may be beneficial for specific patient populations are also highlighted.
The issue includes 13 articles in 65 pages
Management of atrial fibrillation in bradyarrhythmias
No full textSinus node disease (SND), a common indication to implant a pacemaker, is frequently associated with atrial fibrillation (AF), either at implantation (paroxysmal AF) or during follow-up, which often evolves to persistent or permanent AF. Pacemakers with an atrial lead allow continuous monitoring of the atrial rhythm and enable detection of the burden of AF. Asymptomatic atrial tachyarrhythmias, being associated with increased risk of stroke, have important prognostic implications, and their detection could guide decision-making about antithrombotic prophylaxis. Pacing mode and pacing algorithms can influence the occurrence of AF and atrial tachyarrhythmias. In DDD/DDDR pacing mode, reduction of unnecessary right ventricular pacing positively affects the occurrence and evolution of AF, but patients with a history of atrial tachyarrhythmias maintain an increased risk of arrhythmic events. In the MINERVA study, the use of algorithms that act in the atrium for preventive pacing and atrial antitachycardia pacing while minimizing right ventricular pacing was beneficial in patients with SND and previous atrial tachyarrhythmias, and was associated with a significant reduction in evolution to permanent AF. New information available on therapies delivered at the atrial level by implanted devices suggests clinical advantages that could improve current guidelines for the management of AF and atrial tachyarrhythmias
- …
